{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:55:46Z","timestamp":1791078946536,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,20]]},"DOI":"10.7759\/cureus.11591","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T14:37:00Z","timestamp":1605883020000},"source":"Crossref","is-referenced-by-count":3,"title":["Bexarotene: A Rare Cause of Misleading Thyroid Function Tests"],"prefix":"10.7759","author":[{"given":"Vishwanath","family":"Pattan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Schaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Sundaresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S61308","article-title":"The utility of bexarotene in mycosis fungoides and S\u00e9zary syndrome","volume":"8","author":"Panchal MR","year":"2015","unstructured":"Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and S\u00e9zary syndrome. Onco Targets Ther. 2015, 8:367-373. 10.2147\/OTT.S61308","journal-title":"Onco Targets Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman SI","year":"1999","unstructured":"Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999, 340:1075-1079. 10.1056\/NEJM199904083401404","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/mend.11.4.9905","article-title":"The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity","volume":"11","author":"Haugen BR","year":"1997","unstructured":"Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X receptor-gamma1 mediates 9-cis-retinoic acid suppression of thyrotropin-beta promoter activity. Mol Endocrinol. 1997, 11:481-489. 10.1210\/mend.11.4.9905","journal-title":"Mol Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0303-7207(97)00099-3","article-title":"The rat TSHbeta gene contains distinct response elements for regulation by retinoids and thyroid hormone","volume":"8","author":"Breen JJ","year":"1997","unstructured":"Breen JJ, Hickok NJ, Gurr JA. The rat TSHbeta gene contains distinct response elements for regulation by retinoids and thyroid hormone. Mol Cell Endocrinol. 1997, 8:137-146. 10.1016\/s0303-7207(97)00099-3","journal-title":"Mol Cell Endocrinol"},{"key":"ref5","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic M","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, et al.. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001, 137:581-593.","journal-title":"Arch Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic M","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, et al.. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001, 19:2456-2471. 10.1200\/JCO.2001.19.9.2456","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick JJ","year":"2013","unstructured":"Scarisbrick JJ, Morris S, Azurdia R, et al.. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013, 168:192-200. 10.1111\/bjd.12042","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13975","article-title":"Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies","volume":"91","author":"Makita N","year":"2019","unstructured":"Makita N, Manaka K, Sato J, Mitani K, Nangaku M, Iiri T. Bexarotene-induced hypothyroidism: characteristics and therapeutic strategies. Clin Endocrinol (Oxf). 2019, 91:195-200. 10.1111\/cen.13975","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/44851-bexarotene-a-rare-cause-of-misleading-thyroid-function-tests","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:07Z","timestamp":1707506647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/44851-bexarotene-a-rare-cause-of-misleading-thyroid-function-tests"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.11591","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}